Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.
about
Organophosphates dysregulate dopamine signaling, glutamatergic neurotransmission, and induce neuronal injury markers in striatumStimulatory effect of α-synuclein on the tau-phosphorylation by GSK-3βParkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitroLRRK2 phosphorylates novel tau epitopes and promotes tauopathyNovel therapeutics for Alzheimer's disease: an updateProtein phosphatases and Alzheimer's diseaseNMR Meets Tau: Insights into Its Function and PathologyImplications of GABAergic Neurotransmission in Alzheimer's DiseaseTau missorting and spastin-induced microtubule disruption in neurodegeneration: Alzheimer Disease and Hereditary Spastic ParaplegiaSex Hormones Regulate Cytoskeletal Proteins Involved in Brain PlasticityPhysicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs)Physiological and pathological phosphorylation of tau by Cdk5Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targetsClinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkersPhosphodiesterases in neurodegenerative disordersAge-dependent neuroinflammation and cognitive decline in a novel Ala152Thr-Tau transgenic mouse model of PSP and AD.Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8Tau StructuresCeramides in Alzheimer's Disease: Key Mediators of Neuronal Apoptosis Induced by Oxidative Stress and Aβ AccumulationOverexpression of 14-3-3z promotes tau phosphorylation at Ser262 and accelerates proteosomal degradation of synaptophysin in rat primary hippocampal neuronsEarly growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brainModulation of GSK-3β activity in Venezuelan equine encephalitis virus infectionDementia, Preclinical Studies in Neurodegeneration and its Potential for Translational Medicine in South AmericaZebrafish models of TauopathyCritical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer's disease.Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau.Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease.Alzheimer disease: a tale of two prionsTGF-β induces TIAF1 self-aggregation via type II receptor-independent signaling that leads to generation of amyloid β plaques in Alzheimer's disease.Pseudomonas aeruginosa exotoxin Y is a promiscuous cyclase that increases endothelial tau phosphorylation and permeabilityAlpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.Roles of tau protein in health and disease.Tau phosphorylation induced by severe closed head traumatic brain injury is linked to the cellular prion proteinDocking Studies and Biological Evaluation of a Potential β-Secretase Inhibitor of 3-Hydroxyhericenone F from Hericium erinaceus.Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease.Silencing [Formula: see text] Rescues Tau Pathologies and Memory Deficits through Rescuing PP2A and Inhibiting GSK-3β Signaling in Human Tau Transgenic Mice.Stem cell models of Alzheimer's disease: progress and challenges.Declining phosphatases underlie aging-related hyperphosphorylation of neurofilaments.Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's diseaseDrosophila melanogaster in the study of human neurodegeneration.
P2860
Q23918184-99FBA1F8-F10E-4630-AD2E-3FE1B02933E4Q24292861-1D40F3F2-0B23-4D2C-B1EF-04A28E3C3F1AQ24311461-6EA9336F-55CE-4DE0-BF36-3DABEDEAAEE4Q24338188-577D679C-EC13-4BDD-B3FA-20F2550CD7CEQ24620383-EA582B7B-7AFD-41D4-B40A-2B484A633217Q24632495-53C97176-93BE-498E-B6B1-2488B4F13611Q26747418-B1DC0699-62F9-459C-9123-BD0A629CD8D0Q26768593-028ACCE9-1A26-4C5A-B2B9-5E71E1D41F86Q26774045-E7F94BBC-95C7-4216-8831-DADBBB9A03CCQ26774762-3FD2C489-21A4-4634-933D-41B11F0CCA11Q26823798-9151CEC3-E327-4D86-B7BB-3B333D992355Q26860395-C228E359-500A-4B93-AFA8-9C164BD53556Q26865654-B69B912E-15FC-4592-A989-BC33F780FEF1Q27008249-50BC418B-9BB6-4DE2-AA77-EFAFE8628A2FQ27026359-BCCD0342-E514-4D4E-AF29-4338733DB49FQ27317039-A6D676F3-5B74-4C94-BDF6-71A5E78029DBQ27703671-24D9E241-7A73-485E-88D2-4B3075092218Q28076921-51A4FD4E-AFF6-4A13-B022-B5A3030C6B6EQ28087030-FF8A7ECE-5848-4A6B-BF5E-0081CB67A55CQ28537815-49D84276-7D39-4952-8642-F0D1D03A96FFQ28578526-07E85D91-FE81-4956-9C89-DE205041C302Q28730748-D1C7B9D3-934C-42E9-A4FB-C9488EF1E9F8Q28817091-C7A1B43D-9E00-41E1-9647-6E1DF8C232A7Q28833507-38ADE922-EFE8-4F2D-87B5-D3851F60BCC6Q30008912-4A969ACB-C028-45DD-9A61-F6D4943E46FAQ30010481-A29A6C98-001B-41A8-8E54-9B4B4E2BDC15Q30414554-70473CD8-2FA9-410A-8F28-5EADB6CAF438Q30415581-159F9547-4301-46F8-B561-18AC1B5FAEF9Q30498066-11DB23EE-1E2F-4B1B-AA02-E9E0563F28ECQ30523756-193BB341-6961-46E0-B5E1-E7A4FDE44A19Q33552220-306ABA3F-BC42-4CD8-BDBF-8B41EB6DF343Q33559303-E4D6BB22-6EA9-4BA9-B01F-5687CE7B770DQ33576693-6B49C321-350A-4F21-AC3B-F8A421EAAD1EQ33665730-700FD671-9259-4BBA-A581-802BD6900829Q33687072-F24ECA21-DA05-4647-A22A-427BD9A35BC0Q33766526-B5E4A963-687A-45AA-8F53-78BC5F34D6F1Q33796378-3961EDCF-38FD-40FA-966E-8C207032508BQ33937493-10B55DC4-C87F-4CF0-81B9-5115056C48C5Q33980640-E41A8558-A85D-4E15-8958-58C5ED98B0E0Q34022667-19E6AC27-55E8-442E-B182-1BE5FFEA1396
P2860
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.
@en
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.
@nl
type
label
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.
@en
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.
@nl
prefLabel
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.
@en
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.
@nl
P1476
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease.
@en
P2093
Brian H Anderton
P304
P356
10.1016/J.MOLMED.2009.01.003
P577
2009-02-24T00:00:00Z